Singulex
Immunodiagnostics Firm Singulex Shutters Abruptly
The Almeda, California immunodiagnostics developer had been developing immunoassay technologies for 16 years, with ties to many giants in the industry.
The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.
Federal Court Issues $114M Judgement Against Lab Ex-CEO, Consulting Firm Founders in Kickback Case
Defendants were found liable for paying kickbacks that resulted in physician referrals for unnecessary tests.
AACC Publishes High-Sensitivity Troponin Assay Practice Recommendations in Anticipation of More FDA Approvals
Practice recommendations could serve as a guide for labs considering using the high-sensitivity assays as they become available, authors said.
The company has been focused on commercializing its technology for heart attack assessment, but the new data shows how it could be used for CAD risk, as well.
Jun 1, 2017
Singulex's Troponin Assay Gets CE Marking
May 12, 2017
Apr 17, 2017
Singulex Closes $50M Debt Facility
Apr 3, 2017
Singulex Receives CE Mark for Sgx Clarity System
Jan 10, 2017